Refucil Tablets (Griseofulvin BP 500mg)
₦16,000.00
Refucil Tablets contain griseofulvin, an antifungal medication used to treat various fungal infections of the skin, hair, and nails. It is particularly effective against dermatophyte infections.
Key Features:
- Active Ingredient:
- Griseofulvin BP (500 mg): A fungistatic agent that works by inhibiting the growth of fungi and preventing their reproduction.
- Indications:
- Treatment of dermatophyte infections, including:
- Tinea capitis (scalp ringworm)
- Tinea corporis (ringworm of the body)
- Tinea pedis (athlete’s foot)
- Tinea cruris (jock itch)
- Onychomycosis (fungal infections of the nails)
- Treatment of dermatophyte infections, including:
- Dosage Form:
- Available as tablets, typically dosed at 500 mg for ease of administration.
Usage:
- Dosage:
- Follow the healthcare provider’s instructions regarding dosage. Commonly, adults may take 500 mg daily, with adjustments based on the specific infection and patient response.
- Administration:
- Take the tablet with a full glass of water. It is advisable to take it with food to enhance absorption.
Precautions:
- Allergies:
- Inform your healthcare provider about any known allergies to griseofulvin or other medications.
- Side Effects:
- Possible side effects may include gastrointestinal disturbances (nausea, vomiting), headache, dizziness, and allergic reactions. Severe side effects should be reported immediately.
- Interactions:
- Discuss all medications and supplements you are taking with your healthcare provider, as griseofulvin can interact with certain drugs, including anticoagulants and birth control pills.
Storage:
- Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
- Very secured payment methods
- Shipping will be calculated on checkout
- Please note that price may increase due to exchange rate, ensure updated price before making payment
Dispensing supervised byPharm. Tope Kareem, B.PharmPCN Reg. 023669
Last updated 28 August 2026How we write and check this informationPCN Premises Licence LAG20247B39C9




